---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038592"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:15:29.154057+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients

## Summary
- Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).
- Phase 1 ELIMINATE-B trial: PBGENE-HBV showed 47-69% HBsAg reduction in all 3 Cohort 1 patients; one patient had durable ~50% reduction at 7 months.
- Cohort 2 safety data showed no Grade>2 AEs; DMC recommended enrolling Cohort 3. Cash runway extended to H2 2027 via operating cost cuts of ~$25M/year.
- PBGENE-DMD: FDA granted Rare Pediatric Disease and Orphan Drug designations; IND/CTA filing targeted by end of 2025 with clinical data in 2026.
- Total operating expenses fell $3.9M YoY to $21.9M; cash and equivalents $84.8M as of June 30, 2025.

## SEC filing metadata
- accession: 0001628280-25-038592
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/0001628280-25-038592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/dtil-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038592
- JSON: https://secwatch.observer/filing/0001628280-25-038592.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.